{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:38:55Z","timestamp":1793299135944,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006636","name":"University of Maryland, Baltimore County","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.diabres.2025.112039","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T14:53:56Z","timestamp":1738940036000},"page":"112039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study"],"prefix":"10.1016","volume":"221","author":[{"given":"Rozalina G.","family":"McCoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Vandergrift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112039_b0005","unstructured":"CDC. National Diabetes Statistics Report. Atlanta, Georgia, U.S.A.: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2024."},{"key":"10.1016\/j.diabres.2025.112039_b0010","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Standards of Care in Diabetes-2025. Section 9. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2025;48:S181-s206.","DOI":"10.2337\/dc25-S009"},{"issue":"102","key":"10.1016\/j.diabres.2025.112039_b0015","first-page":"S1","article-title":"Clinical practice guideline for diabetes management in chronic kidney disease","volume":"2022","author":"Kdigo","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2025.112039_b0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2025.112039_b0025","doi-asserted-by":"crossref","DOI":"10.2337\/dc20-2977","article-title":"Second-line therapy for type 2 diabetes management: the treatment\/benefit paradox of cardiovascular and kidney comorbidities","author":"McCoy","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112039_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.112039_b0035","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber Patterns ofSGLT2i After Expansions of U.S.Foodand Drug Administration Labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2025.112039_b0040","doi-asserted-by":"crossref","unstructured":"McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Paradox of Glycemic Management: Multimorbidity, Glycemic Control, and High-Risk Medication Use Among Adults With Diabetes. BMJ Open Diabetes Res Care. 2020;In Press.","DOI":"10.1136\/bmjdrc-2019-001007"},{"key":"10.1016\/j.diabres.2025.112039_b0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2022.02.013","article-title":"Correlates of glucagon-like peptide-1 receptor agonist use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus (from the Department of Veterans Affairs)","volume":"172","author":"Al Rifai","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2025.112039_b0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 Inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the department of veterans affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112039_b0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2025.112039_b0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.112039_b0065","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2019.0213","article-title":"Adoption of New Glucose-Lowering Medications in the U.S. - the case of SGLT2 inhibitors: Nationwide cohort study","author":"McCoy","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2025.112039_b0070","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12020-021-02710-4","article-title":"Race and sex differences in the initiation of diabetes drugs by privately insured US adults","volume":"73","author":"McCoy","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.diabres.2025.112039_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure\u2013, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.112039_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004431","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"King","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2025.112039_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2022.3839","article-title":"Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice","volume":"8","author":"Nanna","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2025.112039_b0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2023.05.002","article-title":"Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry","volume":"263","author":"Arnold","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2025.112039_b0095","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/dom.15032","article-title":"Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study","volume":"25","author":"Arnold","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112039_b0100","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s13300-022-01320-1","article-title":"Real-world treatment patterns of glucose-lowering agents among patients with type 2 diabetes mellitus and cardiovascular disease or at risk for cardiovascular disease: an observational, cross-sectional","volume":"13","author":"Nair","year":"2022","journal-title":"Retrospective Study Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.112039_b0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the united states with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2025.112039_b0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. HealthSystems","volume":"84","author":"Shin","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2025.112039_b0115","article-title":"Chronic conditions data warehouse","author":"Cms","year":"2024","journal-title":"Centers for Medicare & Medicaid Services (CMS)"},{"key":"10.1016\/j.diabres.2025.112039_b0120","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112039_b0125","unstructured":"CDC. NCHS Urban-Rural Classification Scheme for Counties. Hyattsville, MD, USA: U.S. National Center for Health Statistics. Office of Analysis and Epidemiology; 2017."},{"key":"10.1016\/j.diabres.2025.112039_b0130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.diabres.2025.112039_b0135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"Stata J"},{"key":"10.1016\/j.diabres.2025.112039_b0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1536867X1301300304","article-title":"Computing adjusted risk ratios and risk differences in Stata","volume":"13","author":"Norton","year":"2013","journal-title":"Stata J"},{"key":"10.1016\/j.diabres.2025.112039_b0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3368\/jhr.50.2.317","article-title":"A practitioner\u2019s guide to cluster-robust inference","volume":"50","author":"Cameron","year":"2015","journal-title":"J Hum Resour"},{"key":"10.1016\/j.diabres.2025.112039_b0150","series-title":"Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US)","article-title":"Diabetes in Older Adults","author":"Laiteerapong","year":"2018"},{"key":"10.1016\/j.diabres.2025.112039_b0155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112039_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2025.112039_b0165","first-page":"S73","article-title":"American diabetes association standards of medical care in diabetes. Section 8. Pharmacologic approaches to glycemic treatment","volume":"41","author":"Ada","year":"2018","journal-title":"Diabetes Care"},{"issue":"41","key":"10.1016\/j.diabres.2025.112039_b0170","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2018","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112039_b0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2019 executive summary","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2025.112039_b0180","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an endocrine society clinical practice guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112039_b0185","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1-S115.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"10.1016\/j.diabres.2025.112039_b0190","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2025.112039_b0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2025.112039_b0200","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FJC.0000000000000864","article-title":"Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center","volume":"76","author":"Hamid","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.diabres.2025.112039_b0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","article-title":"Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits","volume":"224","author":"Gao","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2025.112039_b0210","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.jacc.2019.01.029","article-title":"Prescription of glucagon-like peptide-1 receptor agonists by cardiologists","volume":"73","author":"Vaduganathan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2025.112039_b0215","first-page":"56","article-title":"Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovasc","volume":"9","author":"Gunawan","year":"2020","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112039_b0220","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11606-019-04843-9","article-title":"Primary care provides the majority of outpatient care for patients with diabetes in the US: NAMCS 2009-2015","volume":"34","author":"Pilla","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabres.2025.112039_b0225","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2025.112039_b0230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007682","article-title":"Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes","volume":"14","author":"Thomas","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabres.2025.112039_b0235","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.024482","article-title":"Lessons learned from a patient-centered, team-based intervention for patients with type 2 diabetes at high cardiovascular risk: year 1 results from the cinema program","volume":"11","author":"Neeland","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2025.112039_b0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/ehjcvp\/pvz058","article-title":"Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice","volume":"6","author":"Slater","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.diabres.2025.112039_b0245","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Standards of Care in Diabetes-2025. Section 13. Older Adults. Diabetes Care. 2025;48:S266-s82.","DOI":"10.2337\/dc25-S013"},{"key":"10.1016\/j.diabres.2025.112039_b0250","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jamainternmed.2023.8559","article-title":"Individualizing care for older adults with diabetes amid the revolution in pharmacotherapy","volume":"184","author":"Huang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2025.112039_b0255","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/clinem\/dgac596","article-title":"Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline","volume":"108","author":"McCall","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112039_b0260","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1007\/s11606-021-07331-1","article-title":"Incidence and predictors of primary nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 agonists in a large integrated healthcare system","volume":"37","author":"Luo","year":"2022","journal-title":"J Gen Intern Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:57:17Z","timestamp":1777510637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":52,"alternative-id":["S0168822725000531"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112039","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112039"}}